Nano-X Imaging (NASDAQ: NNOX) Is 'One To Watch'
-
The company combines proprietary imaging hardware, FDA-cleared AI applications, cloud software, radiology services and healthcare IT within an end-to-end platform spanning scan, analysis and interpretation.
Nanox is expanding its commercial reach through its U.S. commercial activities and collaboration with healthcare organizations.
First-quarter 2026 revenue increased to $4.3 million from $2.8 million in the prior-year period, with contributions from teleradiology, imaging systems, OEM services, AI, software and Health IT.
Nanox has secured FDA clearance for Nanox, Nanox X and three Nanox medical imaging solutions, while its commercial and clinical activities involve organizations including RadNet, Cedars-Sinai, Corewell Health and Brigham and Women's Hospital.
Nanox (NASDAQ: NNOX) is focused on driving the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to...
Read More>>
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:
The latest news and updates relating to NNOX are available in the company's newsroom at
Contact IBN
[email protected]
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment